Thelansis’s “Global Primary Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Primary hyperoxaluria is a rare inherited metabolic disorder, most commonly type 1, in which a defective liver enzyme causes excessive oxalate production. This leads to recurrent kidney stones, progressive calcium oxalate deposition, declining kidney function, and, in advanced disease, systemic oxalosis affecting multiple organs. Historically, patients with kidney failure often required combined liver–kidney transplantation because replacing the liver was the only way to correct the underlying metabolic defect. The introduction of RNA interference therapies has transformed care by reducing hepatic oxalate production without transplantation, marking one of the clearest examples of gene-silencing technology entering routine clinical practice, including in children. Lumasiran and nedosiran target different enzymes in the oxalate production pathway, although their approved indications vary by disease subtype and regulatory region.
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Global Primary Hyperoxaluria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report
Our team will get in touch with you shortly about the Global Primary Hyperoxaluria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035 report.